Smarter. Stronger. Together. Expert Guidance, Tools, and Resources to Optimize the Care of Patients With HER2-Negative Early-Stage Breast Cancer

Get up to date on the multidisciplinary care of patients with HER2-negative early-stage breast cancer with this comprehensive educational program featuring Medical Minute modules, downloadable slides, topical commentaries, a patient resource, and an interactive decision support tool providing case-specific treatment recommendations from an expert panel.

Share

Program Content

Activities

Challenges for HER2neg EBC
Current Challenges With Individualizing Therapy for HER2-Negative Early-Stage Breast Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: April 03, 2024

Expires: April 02, 2025

Dilemmas in HER2neg EBC
Clinical Dilemmas When Selecting Adjuvant Therapy for HER2-Negative Early-Stage Breast Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 19, 2024

Expires: July 18, 2025

Activities

Adjuvant CDK Inhibitors for EBC
Integrating Adjuvant CDK4/6 Inhibitors Into Care of Patients With HR-Positive/HER2-Negative Early-Stage Breast Cancer
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: May 01, 2024

Expires: April 30, 2025

BRCA Testing and Targeting in EBC
Germline BRCA Testing and Targeting in HER2-Negative Early-Stage Breast Cancer
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: May 07, 2024

Expires: May 06, 2025

ICIs for EBC
Immune Checkpoint Inhibitor Therapy for HER2-Negative Early-Stage Breast Cancer
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: May 13, 2024

Expires: May 12, 2025

Activities

Adjuvant CDK Inhibitors for EBC Slides
Integrating Adjuvant CDK4/6 Inhibitors Into Care of Patients With HR-Positive/HER2-Negative Early-Stage Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 01, 2024

Expires: April 30, 2025

BRCA Testing and Targeting in EBC Slides
Germline BRCA Testing and Targeting in HER2-Negative Early-Stage Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 07, 2024

Expires: May 06, 2025

ICIs for EBC Slides
Immune Checkpoint Inhibitor Therapy for HER2-Negative Early-Stage Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 16, 2024

Expires: May 15, 2025

Activities

Adjuvant Tx HER2 Negative EBC
Adjuvant Therapy for HER2-Negative Early Breast Cancer: Interactive Decision Support Tool
Tool
Congratulations: You achieved a completion on 04/09/2022

Released: August 22, 2024

Expires: August 21, 2025

Activities

HER2neg EBC Patient Resource
Oral Treatments for HER2-Negative Early-Stage Breast Cancer: A Guide for Patients and Caregivers
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2024

Expires: June 04, 2025

Faculty

cover img faculity

Tanya Gupta, MD

Palo Alto Medical Foundation
Palo Alto, California

cover img faculity

Laura Huppert, MD

Assistant Professor of Medicine
Division of Hematology/Oncology
University of California, San Francisco
San Francisco, California

cover img faculity

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

cover img faculity

Julia A LaBarbera, MSN, RN, AGACNP-BC

Nurse Practitioner
UCLA Hematology Oncology
Santa Monica, California

cover img faculity

Reshma Mahtani, DO

Chief of Breast Medical Oncology
Miami Cancer Center
Baptist Health South Florida
Miami, Florida

cover img faculity

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Cancer Center
Harvard Medical School
Boston, Massachusetts

cover img faculity

Tiffany A Traina, MD, FASCO

Associate Attending, Breast Medicine Service
Vice Chair, Department of Medicine
Section Head, TNBC Clinical Research Program
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medicine
New York, New York

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC in partnership with Breastcancer.org

Supporters

Supported by educational grants from AstraZeneca, Merck Sharp & Dohme, LLC, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Partners

Breastcancer.org

ProCE Banner